Adatanserin
Alternative Names: WAY SEB 324; WY 50324Latest Information Update: 10 Aug 2009
At a glance
- Originator Wyeth
- Developer Fabre-Kramer Pharmaceuticals; Wyeth
- Class Antidepressants; Anxiolytics; Piperazines; Pyrimidines
- Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 21 Mar 2002 Phase-II clinical trials in Anxiety disorders in European Union (PO)
- 21 Mar 2002 Phase-II clinical trials in Anxiety disorders in USA (PO)
- 21 Mar 2002 Phase-II clinical trials in Depression in European Union (PO)